Fox News correspondent Gillian Turner has the latest on the president's focus amid calls for an impeachment inquiry on'Special Report.' House Democrats are launching a working group aimed at crafting artificial intelligence policy, the latest attempt by federal lawmakers to wrap their heads around legislating the rapidly-advancing sector. The New Democrat Coalition, a group of nearly 100 House Democrats that touts itself as "pragmatic," unveiled the new initiative this week. Rep. Don Beyer, D-Va., one of the initiative's vice chairs, told Fox News Digital he hopes the working group will "help develop real, practicable ideas that will put guardrails in place for AI. "I continue to be focused on a variety of areas related to AI, including safety and security, transparency, the future of work, preventing civil rights abuses, health care and suicide prevention, and more, and have discussions ongoing about legislation in these areas with members of both parties," Beyer said. "Congress has to get up to speed on this issue, and I think the New Dems' AI working group will be a constructive setting for progress." The Biden administration and Congress are examining how to regulate AI. Working group Chair Rep. Derek Kilmer, D-Wash., suggested it could lay the groundwork for an AI regulatory framework in the House of Representatives. "We are already seeing how breakthroughs in this emerging technology present both great opportunities and challenges with potential disruptions for workers, for democracy, and for national security," Kilmer said. "As AI's applications expand and change, it is incumbent on lawmakers to address its unique opportunities and challenges by creating a regulatory framework that both encourages growth while guarding against potential risks." WHAT IS ARTIFICIAL INTELLIGENCE (AI)? Rep. Seth Moulton, D-Mass., another member of the working group and a Marine veteran, said he was concerned with how AI would "transform warfare" and called on Congress to put up responsible guardrails against the technology's most devastating possibilities. "It's going to be impossible for Congress to really stay ahead of AI, but what we can and should do is to take very seriously AI's most dangerous use cases and develop solutions and safeguards that apply directly to those cases," Moulton told Fox News Digital. "I'm also particularly concerned about how AI will transform warfare.

While Artificial Intelligence (AI) technologies are progressing fast, compliance costs have become a huge financial burden for AI startups, which are already constrained on research & development budgets. This situation creates a compliance trap, as many AI startups are not financially prepared to cope with a broad spectrum of regulatory requirements. Particularly, the complex and varying regulatory processes across the globe subtly give advantages to well-established and resourceful technology firms over resource-constrained AI startups [1]. The continuation of this trend may phase out the majority of AI startups and lead to giant technology firms' monopolies of AI technologies. To demonstrate the reality of the compliance trap, from a field deployment perspective, we delve into the details of compliance costs of AI commercial operations.

The American Medical Informatics Association wants the Food and Drug Administration to improve its conceptual approach to regulating medical devices that leverage self-updating artificial intelligence algorithms. The FDA sees tremendous potential in healthcare for AI algorithms that continually evolve--called "adaptive" or "continuously learning" algorithms--that don't need manual modification to incorporate learning or updates. While AMIA supports an FDA discussion paper on the topic released in early April, the group is calling on the agency to make further refinements to the Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD). "Properly regulating AI and machine learning-based SaMD will require ongoing dialogue between FDA and stakeholders," said AMIA President and CEO Douglas Fridsma, MD, in a written statement. "This draft framework is only the beginning of a vital conversation to improve both patient safety and innovation. We certainly look forward to continuing it."